Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
Hematology
Does treating CLL reduce the risk of non-melanoma skin cancers?
Related Questions
How do you approach c-KIT mutated, core binding factor (CBF) AML?
What is your preferred first-line treatment regimen for patients with high-risk MDS?
Is there therapeutic relevance for FLT3-ITD mutation in relapsed APML?
How do you manage persistent cytopenias after FCR chemotherapy for treatment of CLL?
What is your approach to management of relapsed/refractory T-cell prolymphocytic leukemia (T-PLL)?
In patients with post-PV myelofibrosis who are ineligible for allogeneic stem cell transplant, how do you approach symptomatic splenomegaly refractory to splenic radiation and ruxolitinib?
Can AMPLIFY data be extrapolated to use of other BTKi's in combination with venetoclax or would you only ever use acalabrutinib/venetoclax in first line?
How would you manage a patient with polycythemia and MPN symptoms (aquagenic pruritus, fatigue) that is JAK2/CALR/MPL negative but peripheral blood NGS positive for IDH2?
If a bone marrow biopsy reveals mast cell leukemia, would you consider treating with avapritinib?
In an elderly transplant ineligible IDH1-mutated patient with AML, who is in remission after 6 cycles of azacitidine and ivosidenib, would you discontinue azacitidine after cycle 6 and continue maintenance ivosidenib until progression/toxicity or continue both azacitidine and ivosidenib?
